EGYPT – Pharma giant Novartis Egypt, with support from the Egyptian Vitreoretinal Society (EGVRS), has launched its nationwide campaign christened “Art of Vision” to raise public awareness of retinal diseases.

The “Art of Vision” campaign will focus on the early detection of eye conditions while spreading professional knowledge to the public on ways to protect their vision from preventable blindness.

With a special focus on the elderly population, Novartis Egypt’s initiative aligns with its mission of reimagining medicine to improve and extend people’s lives.

The initiative will pave the way for proper preventive measures and timely comprehensive eye care, particularly bringing new hope for patients with diabetic retinopathy and wet eye atrophy.

It will build upon the ongoing efforts of Novartis Egypt in supporting health authorities and medical associations to educate Egyptians about retinal diseases and provide them with effective treatment plans.

People aged 50 and over in Egypt were advised to have regular retina examinations for early disease detection, while ones affected by presbyopia were encouraged to educate themselves about its treatment for optimal results and vision quality preservation.

The awareness campaign was launched during the annual Egyptian Vitreoretinal Society conference held at the Marriott Mena House in Cairo from 1st March to 3rd March 2023.

Speaking at the campaign launch ceremony, Mohamed Abdelmotagaly, InMArket Brands & Business Innovation (IBBI) Head at Novartis Egypt, emphasized the company’s commitment to providing innovative medicines and promoting advances in science.

Dr. Abdelmotagaly said that Novartis Egypt’s “Art of Vision” campaign will be rolled out in conjunction with the EGVRS to elevate awareness around retinal diseases and their effects on vision.

He further said that the joint initiative will help patients to better understand the symptoms of ocular diseases as well as encourage people to utilize available resources to decrease the impact of eye problems.

In addition, Novartis Egypt and EGVRS will continue to equip the Egyptian community with awareness and vital information regarding retinal diseases.

The pharmaceutical company’s strategy focuses on enhancing its investments in Egypt, especially in areas of innovation and technology transfer.

Meanwhile, Novartis Egypt and Cleopatra Hospitals Group (CHG), Egypt’s best provider of medical and healthcare services, recently entered into a strategic partnership deal to provide the best healthcare services to atherosclerotic cardiovascular disease (ASCVD) patients.

Sandoz Egypt Pharma, a division of the Novartis Group, also entered into a distribution and promotion agreement with Ibnsina Pharma, the fastest-growing and second-largest pharmaceutical distributor in Egypt, for the Sandoz over-the-counter (OTC) portfolio of products.

Novartis Egypt is taking bold steps in supporting Egypt’s efforts to become a regional healthcare hub, along with supporting exports of the Egyptian pharmaceutical sector.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.